Virtus ETF Advisers’s Keros Therapeutics KROS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,857	Closed	-$61.1K	–	621
2024 Q4	$61.1K	Buy	3,857 +1,998	+107%	+$104K	0.02%	446
2024 Q3	$108K	Buy	1,859 +30	+2%	+$1.48K	0.05%	365
2024 Q2	$83.6K	Sell	1,829 -738	-29%	-$39.7K	0.04%	386
2024 Q1	$170K	Sell	2,567 -176	-6%	-$10.4K	0.09%	305
2023 Q4	$109K	Buy	2,743 +182	+7%	+$5.71K	0.07%	332
2023 Q3	$81.6K	Sell	2,561 -257	-9%	-$9.59K	0.05%	357
2023 Q2	$113K	Buy	2,818 +801	+40%	+$35.1K	0.07%	336
2023 Q1	$86.1K	Sell	2,017 -771	-28%	-$38.9K	0.05%	373
2022 Q4	$134K	Sell	2,788 -1,037	-27%	-$48.4K	0.07%	382
2022 Q3	$144K	Buy	3,825 +32	+0.8%	+$1.11K	0.06%	359
2022 Q2	$105K	Buy	3,793 +568	+18%	+$24.9K	0.04%	420
2022 Q1	$175K	Sell	3,225 -191	-6%	-$9.8K	0.08%	208
2021 Q4	$200K	Sell	3,416 -600	-15%	-$29.9K	0.08%	209
2021 Q3	$159K	Sell	4,016 -213	-5%	-$7.58K	0.07%	328
2021 Q2	$180K	Buy	4,229 +394	+10%	+$21.3K	0.07%	386
2021 Q1	$236K	Buy	3,835 +77	+2%	+$4.88K	0.1%	299
2020 Q4	$265K	Buy	+3,758	New	+$237K	0.11%	290